Molecular Partners AG MLLCF

Full chart Compare

Set alert

4.01 USD 0.00 (+0.00%)

At closeNov 10, 2026, 4:00 PM EST

2.55 Day range 2.55

2.25 52-week range 4.85

YTD: +14.57%
1 year: +11.39%

News

9 months ago seekingalpha.com Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
9 months ago seekingalpha.com Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12 months ago seekingalpha.com Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program Transcript Molecular Partners AG ( MOLN ) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program November 12, 2025 10:00 AM EST Company Participants Patrick Amstutz - Co-Founder,…
1 year ago seekingalpha.com Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript Molecular Partners AG (NASDAQ:MOLN ) Q4 2024 Earnings Conference Call March 7, 2025 8:00 AM ET Company Participants Michael Tobias Stumpp - EVP Projects Patrick Amstutz - Co-Founder & CEO Philippe…
2 years ago seekingalpha.com Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript Molecular Partners AG (MOLN) Q4 2023 Earnings Call Transcript
3 years ago seekingalpha.com Molecular Partners AG (MOLN) Q4 2022 Earnings Call Transcript Molecular Partners AG (NASDAQ:MOLN ) Q4 2022 Earnings Conference Call March 10, 2023 8:00 AM ET Company Participants Seth Lewis - Senior Vice President, Investor Relations Patrick Amstutz - Chief…
4 years ago seekingalpha.com Molecular Partners AG (MOLN) Q2 2022 Earnings Call Transcript Molecular Partners AG (NASDAQ:MOLN ) Q2 2022 Earnings Conference Call August 25, 2022 8:00 AM ET Company Participants Seth Lewis - SVP of IR Patrick Amstutz - CEO Andreas Emmenegger - CFO Conference…
5 years ago benzinga.com Molecular Partners - Novartis' COVID-19 Antiviral Shows Encouraging Preclinical Action Against Delta Variant Molecular Partners AG (NASDAQ: MOLN) reported on the clinical progress of its antiviral candidate, ensovibep, as part of a presentation with its partner Novartis AG (NYSE: NVS) at the Credit Suisse…
5 years ago accesswire.com Molecular Partners Announces Pricing of Initial Public Offering of American Depositary Shares in the United States ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / June 15, 2021 / Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin®…
5 years ago accesswire.com Molecular Partners Announces First Patient Dosed in COVID-19 NIH-Sponsored ACTIV-3 Trial Evaluating Antiviral Candidate Ensovibep Global Phase 3 trial designed to investigate safety and efficacy of ensovibep in hospitalized adults with COVID-19 Ensovibep receives U.S. FDA Fast Track Designation for the treatment of COVID-19 in…
5 years ago zacks.com Novartis (NVS) & Molecular Partners Initiate Study for COVID-19 Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.
5 years ago accesswire.com Molecular Partners to Present Data from Localized Immune Agonist (MP0317), T-cell Engager, and Peptide-MHC Immunotherapy Programs at AACR Annual Meeting ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / March 10, 2021. Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as…